
<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <title>Hypertension in Adults - Full Summary</title>
    <style>
        body {
            font-family: Arial, sans-serif;
            line-height: 1.6;
            margin: 40px;
            background-color: #f9f9f9;
            color: #333;
        }
        h1, h2, h3 {
            color: #2a5d84;
        }
        table {
            border-collapse: collapse;
            width: 100%;
            margin: 20px 0;
            background-color: #fff;
        }
        th, td {
            border: 1px solid #ccc;
            padding: 10px;
            text-align: left;
        }
        th {
            background-color: #e1ecf4;
        }
        code {
            background: #f4f4f4;
            padding: 2px 4px;
            font-size: 90%;
        }
    </style>
</head>
<body>
    <h1>Comprehensive Summary of Hypertension in Adults (UpToDate 2024)</h1>

    <h2>1. Definition and Classification</h2>
    <p>Hypertension is defined as:</p>
    <ul>
        <li><strong>ACC/AHA:</strong> &ge;130/80 mmHg</li>
        <li><strong>ESC/ESH:</strong> &ge;140/90 mmHg</li>
    </ul>
    <table>
        <tr><th>Category</th><th>Systolic (mmHg)</th><th>Diastolic (mmHg)</th></tr>
        <tr><td>Normal</td><td>&lt;120</td><td>&lt;80</td></tr>
        <tr><td>Elevated</td><td>120–129</td><td>&lt;80</td></tr>
        <tr><td>Stage 1</td><td>130–139</td><td>80–89</td></tr>
        <tr><td>Stage 2</td><td>&ge;140</td><td>&ge;90</td></tr>
    </table>

    <h2>2. Epidemiology</h2>
    <ul>
        <li>~1.3 billion people affected globally.</li>
        <li>Most common chronic medical condition.</li>
        <li>Strong links to aging, obesity, diet, and family history.</li>
    </ul>

    <h2>3. Etiology</h2>
    <h3>Primary (Essential) Hypertension</h3>
    <ul>
        <li>Multifactorial – Genetic and environmental.</li>
    </ul>
    <h3>Secondary Hypertension</h3>
    <ul>
        <li>Suspect with early/late onset, resistant HTN, hypokalemia.</li>
        <li>Causes: CKD, RAS, hyperaldosteronism, OSA, medications.</li>
    </ul>

    <h2>4. Diagnosis</h2>
    <ul>
        <li>Use average of &ge;2 readings on &ge;2 visits.</li>
        <li>Prefer ABPM or HBPM for confirmation.</li>
        <li>Ensure proper technique for accuracy.</li>
    </ul>

    <h2>5. Clinical Evaluation</h2>
    <ul>
        <li>History: risk factors, lifestyle, medication use.</li>
        <li>Physical: Fundoscopy, bruits, BMI, pulses.</li>
        <li>Labs: BMP, UA, glucose, lipids, ECG.</li>
    </ul>

    <h2>6. Target Organ Damage</h2>
    <ul>
        <li>LVH, HF, stroke, nephropathy, retinopathy.</li>
    </ul>

    <h2>7. Cardiovascular Risk Assessment</h2>
    <ul>
        <li>Use ASCVD or PCE calculators.</li>
        <li>Supports decisions for therapy initiation.</li>
    </ul>

    <h2>8. Lifestyle Modifications</h2>
    <table>
        <tr><th>Intervention</th><th>Effect (approx.)</th></tr>
        <tr><td>Weight loss</td><td>-1 mmHg per kg</td></tr>
        <tr><td>DASH diet</td><td>-8 to -14 mmHg</td></tr>
        <tr><td>Salt reduction</td><td>-5 mmHg</td></tr>
        <tr><td>Exercise</td><td>-4 to -9 mmHg</td></tr>
        <tr><td>Alcohol moderation</td><td>-2 to -4 mmHg</td></tr>
    </table>

    <h2>9. Pharmacologic Treatment</h2>
    <ul>
        <li>Start in Stage 2 or Stage 1 with risk factors.</li>
        <li>First-line drugs: Thiazides, ACEi, ARB, CCB.</li>
        <li>Beta-blockers reserved for specific indications.</li>
        <li>Consider dual therapy if BP &gt;20/10 above target.</li>
    </ul>

    <h2>10. Treatment Targets</h2>
    <table>
        <tr><th>Population</th><th>Target BP</th></tr>
        <tr><td>General</td><td>&lt;130/80 mmHg</td></tr>
        <tr><td>Older adults</td><td>&lt;140/90 or &lt;130 if tolerated</td></tr>
        <tr><td>CKD, Diabetes, CVD</td><td>&lt;130/80 mmHg</td></tr>
    </table>

    <h2>11. Monitoring</h2>
    <ul>
        <li>Reassess every 1–3 months.</li>
        <li>Monitor for side effects and adherence.</li>
        <li>Check labs if on ACEi/ARB/thiazide.</li>
    </ul>

    <h2>12. Resistant Hypertension</h2>
    <ul>
        <li>BP uncontrolled on 3 meds (including diuretic).</li>
        <li>Evaluate for adherence and secondary causes.</li>
        <li>Add mineralocorticoid antagonists (e.g., spironolactone).</li>
    </ul>

    <h2>13. Hypertensive Crisis</h2>
    <table>
        <tr><th>Type</th><th>BP</th><th>Features</th><th>Management</th></tr>
        <tr><td>Urgency</td><td>&ge;180/120</td><td>No organ damage</td><td>Oral meds, follow-up</td></tr>
        <tr><td>Emergency</td><td>&ge;180/120</td><td>Organ damage present</td><td>IV meds, ICU</td></tr>
    </table>

    <h2>14. Summary Table</h2>
    <table>
        <tr><th>Step</th><th>Action</th></tr>
        <tr><td>Confirm Diagnosis</td><td>ABPM or HBPM</td></tr>
        <tr><td>Risk Assessment</td><td>Use ASCVD/PCE</td></tr>
        <tr><td>Lifestyle</td><td>For all patients</td></tr>
        <tr><td>Medications</td><td>Start per stage/risk</td></tr>
        <tr><td>Targets</td><td>&lt;130/80 (most)</td></tr>
        <tr><td>Follow-up</td><td>1–3 months</td></tr>
        <tr><td>Resistant HTN</td><td>Evaluate & treat</td></tr>
    </table>
</body>
</html>
